- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03026998
MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH) (DepiSCARRH)
January 29, 2024 updated by: Institut Curie
MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma
The purpose of this study is to assess the benefit of MR screening for asymptomatic head & neck (or CNS) second primary cancers occurring in hereditary retinoblastoma patients previously treated by external beam radiation therapy (EBRT).
Study Overview
Detailed Description
Patients with hereditary retinoblastoma treated during infancy by external beam radiation therapy (EBRT) the risk of second primary cancer occurring within radiation fields is high.
The aim of this study is to depict by MRI secondary tumors as early as possible, before the occurrence of clinical symptoms.
Affected patients will be further managed in a national expert center with dedicated diagnostic and treatment procedures.
However, the benefit of such management has to be assessed in terms of prognosis.
Study Type
Interventional
Enrollment (Estimated)
167
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anne JOCHEM
- Phone Number: +33 (0) 56 24 56 01
- Email: anne.jochem@curie.fr
Study Locations
-
-
-
Paris, France, 75005
- Recruiting
- Institut Curie
-
Contact:
- HERVE BRISSE, MD
- Email: herve.brisse@curie.fr
-
Principal Investigator:
- Hervé BRISSE, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Personal history of hereditary retinoblastoma (i.e., familial history of retinoblastoma, or bilateral retinoblastoma, or unilateral multifocal retinoblastoma, or identified germline RB1 mutation or 13q deletion)
- External beam radiation therapy (EBRT) used for retinoblastoma treatment
- Age at inclusion greater or equal to 7 years old.
- Time period between the end of EBRT and inclusion date of 5 years or more
- Written informed consent signed by patient (or legal representative)
Exclusion Criteria:
- Personal history of non-familial unilateral unifocal retinoblastoma without RB1 germline mutation.
- Personal history of second primary neoplasm occurring within radiation fields
- Contraindication for MRI (pacemaker, intraocular metallic foreign body, defibrillators or other implanted electronic devices, intracranial ferro-magnetic clips) or associated conditions preventing from MR examination (intraocular prostheses and implants are not a contraindication for MRI; orthodontic metallic devices are not a contraindication but might decrease the image quality and should be removed, if possible)
- Patients unable to comply with follow-up study requirements, for any geographical, social or psychological reason
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: MRI
|
MRI will be performed each year during 10 years.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the benefit of MR screening for asymptomatic head & neck (or CNS) second primary cancers occurring in hereditary retinoblastoma patients previously treated by external beam radiation therapy (EBRT).
Time Frame: Up to 10 years
|
Rate of patients with R0-resection quality (versus R1 or R2) among patients with second primary cancer depicted by MRI, with comparison to historical series
|
Up to 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the visual prognosis of patients with second primary cancer depicted by MRI
Time Frame: Up to 10 year
|
Measure of residual visual functions before and after local treatment of the second primary cancer in patients depicted by MRI compared to that patients who the second primary cancer was depicted by clinical symptoms.
|
Up to 10 year
|
Assess the feasibility of the MR screening program.
Time Frame: Up to 10 years
|
Number of MRI performed for the radiological follow-up for patients agreeing to participate to the study.
|
Up to 10 years
|
Number of non tumor detected anomalies with invasive procedures to assess the psychological consequences of the MR screening program
Time Frame: Up to 10 years
|
Up to 10 years
|
|
Assess the psychological consequences of the MR screening program by the completion of quality of life questionnaires.
Time Frame: Up to 10 years
|
- Quality of life questionnaires completed by the patient every year (before MRI) during 10 years.
|
Up to 10 years
|
Number of depicted second primary cancer.to assess the diagnostic accuracy of MRI.
Time Frame: Up to 10 years
|
Up to 10 years
|
|
Number of asymptomatic depicted second primary cancer by MR to assess the diagnostic accuracy of MRI
Time Frame: Up to 10 years
|
Up to 10 years
|
|
Number of symptomatic second primary cancer between 2 MRI.to assess the diagnostic accuracy of MRI
Time Frame: Up to 10 years
|
Up to 10 years
|
|
Measure of sensibility of MRI to detect second primary cancer
Time Frame: Up to 10 years
|
Up to 10 years
|
|
Measure of specificity of MRI to detect second primary cancer
Time Frame: Up to 10 years
|
Up to 10 years
|
|
Collection of secondary tumors for future research purpose.
Time Frame: up to 10 years
|
up to 10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hervé BRISSE, MD, NSTITUT CURIE
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 19, 2017
Primary Completion (Estimated)
March 1, 2034
Study Completion (Estimated)
March 1, 2034
Study Registration Dates
First Submitted
January 6, 2017
First Submitted That Met QC Criteria
January 17, 2017
First Posted (Estimated)
January 20, 2017
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Eye Diseases
- Retinal Diseases
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Eye Diseases, Hereditary
- Eye Neoplasms
- Retinal Neoplasms
- Retinoblastoma
- Neoplasms, Second Primary
Other Study ID Numbers
- IC 2015-14 DepISCARRH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Sponsor will share de-identified data sets.
Documents generated under the project will be disseminated in accordance with Institut Curie policies.
IPD Sharing Time Frame
Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.
IPD Sharing Access Criteria
Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).
IPD Sharing Supporting Information Type
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Retinoblastoma
-
Children's Oncology GroupRecruitingBilateral Retinoblastoma | Childhood Intraocular Retinoblastoma | Unilateral Retinoblastoma | Group D Retinoblastoma | Stage I RetinoblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular Retinoblastoma | Recurrent Retinoblastoma | Extraocular RetinoblastomaUnited States, Canada, Puerto Rico
-
Children's Hospital Los AngelesRecruitingRetinoblastoma | Retinoblastoma Bilateral | Retinoblastoma UnilateralUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RecruitingCancer Survivor | Retinoblastoma | Unilateral Retinoblastoma | Intraocular Retinoblastoma | Biological SiblingUnited States, Canada
-
Memorial Sloan Kettering Cancer CenterRecruitingRetinoblastoma | Pediatric RetinoblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular RetinoblastomaUnited States, Canada, Australia, New Zealand, India
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
Amsterdam UMC, location VUmcRecruitingRetinoblastoma | Trilateral RetinoblastomaNetherlands
-
Hospital JP GarrahanHospital San Juan de Dios, SantiagoActive, not recruitingUnilateral RetinoblastomaArgentina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnilateral RetinoblastomaUnited States
Clinical Trials on MRI
-
Assistance Publique Hopitaux De MarseilleActive, not recruitingMultiple SclerosisFrance
-
Cambridge University Hospitals NHS Foundation TrustRecruitingBreast CancerUnited Kingdom
-
Seoul National University Bundang HospitalBayerCompletedTraumaKorea, Republic of
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedOsteosarcoma | Ewing Sarcoma | Paget's DiseaseUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
University of ZurichBalgrist University HospitalNot yet recruiting
-
Bragee ClinicsNot yet recruitingChronic Fatigue Syndrome
-
Brighton and Sussex University Hospitals NHS TrustCompletedLacrimal Duct Obstruction | Lacrimal StenosisUnited Kingdom
-
Rennes University HospitalBayerTerminatedMultiple Sclerosis (MS) | Inflammatory DiseaseFrance
-
Memorial Sloan Kettering Cancer CenterTerminated